Moxiclav (Amoxicillin Trihydrate, Clavulanic Acid)

Amoxicillin trihydrate interferes with bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which prevents the cross‑linking of peptidoglycan strands. This weakens the wall and leads to bacterial lysis. When combined with clavulanic acid, the drug also blocks β‑lactamase enzymes that some bacteria produce to inactivate amoxicillin.

The dosage of Moxiclav is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, and renal function. Only a qualified healthcare professional should set the dose and duration of therapy.

Safety data for Moxiclav in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult a healthcare provider, as the drug can be excreted in breast milk.

To order Moxiclav, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Moxiclav combines amoxicillin with clavulanic acid, a β‑lactamase inhibitor. This combination expands the antibacterial spectrum to include organisms that produce β‑lactamase enzymes, which would otherwise inactivate amoxicillin. Consequently, Moxiclav can treat infections caused by resistant strains that amoxicillin alone may not cover.

Moxiclav tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store them out of reach of children.

Moxiclav is taken orally, usually with food or a full glass of water to improve absorption and reduce gastrointestinal irritation. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and liver enzyme elevations that may indicate hepatic injury. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, persistent diarrhea, or jaundice.

Moxiclav should be avoided in individuals with a known hypersensitivity to penicillins, β‑lactam antibiotics, or any component of the formulation. It is also contraindicated in patients who have experienced a severe reaction to clavulanic acid. Clinicians should assess each patient’s medical history before prescribing.